← Back to headlines
GSK Acquires Nuvalent for $10.6 Billion
Pharmaceutical giant GSK has acquired Nuvalent in a deal valued at $10.6 billion, as part of its strategy to address patent cliffs.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
